Salut òssia en dones afectes de càncer de mama en estadis inicials
Aromatase inhibitors are the gold standard treatment for postmenopausal women with early breast cancer (EBC). The major side effects are bone loss and arthralgias, that can induce treatment discontinuations. Baseline bone health in postmenopausal women is poorly characterised in prospective series o...
| Autor: | |
|---|---|
| Tipo de recurso: | tesis doctoral |
| Fecha de publicación: | 2013 |
| País: | España |
| Institución: | Universitat Autònoma de Barcelona |
| Repositorio: | Dipòsit Digital de Documents de la UAB |
| Idioma: | catalán |
| OAI Identifier: | oai:ddd.uab.cat:127463 |
| Acceso en línea: | https://ddd.uab.cat/record/127463 |
| Access Level: | acceso abierto |
| Palabra clave: | Càncer mama Inhibidors aromatasa Salut òssia |
| Sumario: | Aromatase inhibitors are the gold standard treatment for postmenopausal women with early breast cancer (EBC). The major side effects are bone loss and arthralgias, that can induce treatment discontinuations. Baseline bone health in postmenopausal women is poorly characterised in prospective series of EBC patients candidates to AI therapy. Our objective is to comprehensively evaluate bone health in a prospective clinical cohort of patients recruited prior to adjuvant AI therapy, with the aim of establishing potential AI impact on bone loss and fractures. We consecutively included 343 women with EBC who were about to start adjuvant AI therapy. Participants were assessed before AI initiation and at 3 months, with annual assessments thereafter. Bone mineral density (BMD), spine X-ray, bone metabolism (vitamin D, bone turnover markers), arthralgia and quality of life are measured. The results of our study demonstrates: - Treatment with adjuvant AI decreases BMD 0.6 at 2.36% at 12 months, even thought calcium and vit D treatment were administered following the guidelines. - When patients starts AI the asymptomatic fragility fractures rate was 11.8%. - Baseline vit D levels are suboptimal. Vitamin D insufficiency ( 40 ng/ml. - Bone loss at 12 months is not observed in women on oral bisphosphonates treatment. |
|---|